
Sunday, November 13, 2022 8:29:59 AM
Proof that $3.3 million was "really" spent on starting US trials? They didn't start trials yet, to my knowledge.
No, I have no noticed that anyone dumps stock "en-masse" before PR's. (a) there is no volume to indicate dumping and (b) that makes no sense, to dump BEFORE a PR.
Your DD should have revealed historical toxic financing, reverse splits, dilution, and dumping -- all of which stopped after the last reverse split. I give credit to Cartwright for putting an end to that. I guess that's my frame of reference -- the stock was 15 cent after the last reverse split and it stabilized and went UP after the R/S which is quite unusual in pinksheet penny-stock gambling.
Notice I said "gambling," not "investing." Pinksheet biotechs are not for everyone.
Do I have proof that other directors are "real people?" What else would they be? Are you suggesting that the people named on the SEC filings are fictitious people? That's absurd.

Liked By
Spread the love. Be the first to like this post!
Recent GTHP News
- Annual Report (10-k) • Edgar (US Regulatory) • 03/30/2023 10:04:47 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 03/09/2023 09:31:38 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 02/14/2023 05:56:16 PM
- Notice of Effectiveness (effect) • Edgar (US Regulatory) • 01/26/2023 11:04:32 AM
- Withdrawal of Registration Statement (rw) • Edgar (US Regulatory) • 12/02/2022 10:00:23 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/14/2022 06:40:32 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 09/15/2022 09:31:19 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 08/15/2022 06:29:45 PM
- Statement of Ownership (sc 13g) • Edgar (US Regulatory) • 07/06/2022 08:34:50 PM
- Securities Registration Statement (s-1/a) • Edgar (US Regulatory) • 06/30/2022 10:04:05 AM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 05/16/2022 06:03:28 PM
ILUS Confirms Further Funding Arrangements and Note Settlement • ILUS • Mar 31, 2023 10:21 AM
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K • SIGY • Mar 31, 2023 10:06 AM
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders Conference • TLSA • Mar 31, 2023 7:07 AM
ARway Secures Multiple New SDK Deals to Drive Growth in $44B Indoor Positioning and Navigation Market • ARWYF • Mar 30, 2023 10:30 AM
Nextech3D.ai Enters Asian Market with Major 3D Modeling Deal to Revolutionize E-Commerce • NTAR • Mar 30, 2023 10:00 AM
OMID Posts 2022 Annual Report and Provides Update • OMID • Mar 30, 2023 9:15 AM